Takeda Pharmaceutical Company (4502) Q2 2025 earnings summary

Executive summary

• H1 FY2024 revenue reached JPY 2,384.0 billion, up 13.4% year-over-year (5.0% at CER), driven by 18.7% growth in launch products, now 47% of total revenue.

• Core operating profit margin improved to 30.2% in H1, supported by product mix, R&D phasing, and efficiency program impacts; reported operating profit surged 194% due to fewer impairments and one-time costs.

• Major launches (Fruzaqla, ADZYNMA, Eohilia) exceeded expectations, with rapid uptake and expanded approvals across key markets.

• Vyvanse experienced a slower-than-expected decline in H1, but generic erosion is expected to accelerate in H2, impacting revenue and profit.

• Full-year management guidance was raised, reflecting strong H1 performance, product momentum, and updated FX assumptions.

Financial highlights

• H1 FY2024 revenue: JPY 2,384.0 billion (+13.4% year-over-year, +5.0% CER).

• Core operating profit: JPY 719.9 billion (+22.3% year-over-year, +12.9% CER); margin 30.2%.

• Reported operating profit: JPY 350.6 billion (+194% year-over-year), driven by lower impairments and one-time costs.

• Net profit attributable to owners: JPY 187.3 billion (+352.8% year-over-year); core EPS: 310 yen; reported EPS: 119 yen.

• Adjusted free cash flow: JPY 247.5 billion (vs. -71.1B prior year); operating cash flow: JPY 451.3 billion (+54.9%).

Outlook and guidance

• FY2024 revenue forecast raised to JPY 4,480.0 billion; core operating profit to JPY 1,050.0 billion; core EPS to 456 yen.

• Management guidance at CER: core revenue expected flat to slightly increasing, core operating profit mid-single-digit % decline, core EPS approx. 10% decline.

• Free cash flow forecast range raised; annual dividend plan confirmed at 196 yen per share.

• H2 expected to see increased R&D spend and higher costs due to efficiency program implementation and Vyvanse generic erosion.

• Guidance reflects updated FX assumptions (JPY/USD 150, JPY/EUR 165).